“…This might be attributed to the treatment that often causes visible scarring and disfigurement (Sobanko et al, 2015) as well as the severe concerns of patients that the cancer could spread, recur, or develop (Burdon-Jones, Thomas, & Baker, 2010). As regards the economic burden, skin cancer carries considerable direct and indirect costs that will soar as incidence rates increase (Gordon & Rowell, 2015;Guy et al, 2015;Mofidi et al, 2018;RKI, 2016;Stang, Stausberg, Boedeker, Kerek-Bodden, & J€ ockel, 2008). Direct costs arise from the multifaceted treatment of skin cancer (National Cancer Institute (NCI), 2018a, 2018b), while indirect costs are caused by productivity loss due to temporary or permanent incapacity for work, and premature death (Mofidi et al, 2018;RKI, 2016).…”